(S)-benzyl 5-amino-1-(5-phenyl-1H-1,2,4-triazol-3-yl)pentylcarbamate | 1125843-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-benzyl 5-amino-1-(5-phenyl-1H-1,2,4-triazol-3-yl)pentylcarbamate
• CAS: 1125843-60-8
• 化学式: C₂₁H₂₅N₅O₂
• 分子量: 379.462
• InChiKey: YCPPVDQAQQWARY-SFHVURJKSA-N

物化性质

• 密度：
  1.215±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.57
• 重原子数：
  28.0
• 可旋转键数：
  9.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  105.92
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  氯磺酰异氰酸酯 、 (S)-benzyl 5-amino-1-(5-phenyl-1H-1,2,4-triazol-3-yl)pentylcarbamate 、 叔丁醇 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors

  摘要：

  We have recently reported on a novel class of histone deacetylase (HDAC) inhibitors bearing a sulfamide group as the zinc-binding unit. Herein, we report on the synthesis of sulfamide based inhibitors designed around a lysine scaffold and their structure-activity relationships against HDAC1 and HDAC6 isotypes as well as 293T cells. Our efforts led us to an improvement of the originally disclosed lysine-based sulfamide, 2a to compound 12h which has equal potency in enzyme and cell-based assays as well as enhanced metabolic stability and PK profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.075
• 作为产物：
  描述：

  (S)-tert-butyl 5-(benzyloxycarbonylamino)-5-(5-phenyl-1H-1,2,4-triazol-3-yl)pentylcarbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-benzyl 5-amino-1-(5-phenyl-1H-1,2,4-triazol-3-yl)pentylcarbamate
  参考文献：
  名称：

  Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors

  摘要：

  We have recently reported on a novel class of histone deacetylase (HDAC) inhibitors bearing a sulfamide group as the zinc-binding unit. Herein, we report on the synthesis of sulfamide based inhibitors designed around a lysine scaffold and their structure-activity relationships against HDAC1 and HDAC6 isotypes as well as 293T cells. Our efforts led us to an improvement of the originally disclosed lysine-based sulfamide, 2a to compound 12h which has equal potency in enzyme and cell-based assays as well as enhanced metabolic stability and PK profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.075